Although we have gained further insight into the cytogenetic and molecular abnormalities of MS, such as chromosomal abnormalities like inv (16) and t (8, 21), and mutations in NPM1 and FLT3, the prognostic impact of genetic features remains poorly understood due to the small sample size (16, 36, 37). This evidence concerns the gene NPM1 and myeloid sarcoma.